Oruka Therapeutics, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 02/06/24 | FY 02/05/24 | FY 12/31/23 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | — | — | — | — | $0 |
| Research and development | $100.6M | $75.1M | — | — | $1.0M |
| Operating expenses | $122.1M | $88.1M | — | — | $7.3M |
| Operating income | -$122.1M | -$88.1M | — | — | -$7.3M |
| Interest expense | — | $1.5M | — | — | — |
| Pretax income | -$105.4M | -$83.7M | — | — | — |
| Income tax expense | — | — | — | — | $0 |
| Net income | -$105.4M | -$83.7M | — | — | -$5.3M |
| Balance Sheet | |||||
| Cash and equivalents | $46.9M | $61.6M | — | — | $37.4M |
| Current assets | $343.9M | $376.9M | $1,000 | — | $37.6M |
| Total assets | $488.6M | $396.0M | $1,000 | — | $37.9M |
| Current liabilities | $15.4M | $13.0M | — | — | $637,000 |
| Total liabilities | $16.7M | $13.8M | — | — | $841,000 |
| Total debt | — | — | — | — | $0 |
| Stockholders' equity | $471.9M | $382.2M | $1,000 | $1,000 | $37.0M |
| Cash Flow Statement | |||||
| Cash from operations | -$88.2M | -$57.8M | — | — | -$5.0M |
| Depreciation and amortization | $83,000 | $27,000 | — | — | $15,000 |
| Stock-based compensation | $24.2M | $14.9M | — | — | $686,000 |
| Capital expenditure | $209,000 | $189,000 | — | — | $0 |
| Free cash flow | -$88.4M | -$58.0M | — | — | -$5.0M |
Shares outstanding 60.3M · Free float 36.3%
Annual filing data through FY ended December 31, 2025; float as of July 11, 2026.